Reijo J Backstrom

This inventor holds 19 USPTO granted patents. Top assignees: Orion-Yhtyma Oy, Orion Corporation, Orion Corporation/orion Pharmaceutica. Active years: 1990-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reijo J Backstrom. Retrieved from https://idiyas.com/inventor/reijo-j-backstrom

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 100.0

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 252(Granted Patents)

Company Filing History:

Orion Corporation/orion Pharmaceutica

patent

Years Active: 1990-2000

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6121303 - Pharmacologically active catechol derivatives (2000-09-19),

2. 5889037 - Pharmacologically active catechol derivatives (1999-03-30),

3. 5710343 - Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde (1998-01-20),

4. 5512572 - Anti-ischemic medicament (1996-04-30),

5. 5512571 - (-) (1996-04-30),

6. 5489614 - Catechol derivatives, their physiologically acceptable salts, esters and (1996-02-06),

7. 5446194 - Pharmacologically active catechol derivatives (1995-08-29),

8. 5424428 - ( (1995-06-13),

9. 5362733 - Pharmacologically active catechol derivatives (1994-11-08),

10. 5356923 - 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and (1994-10-18),

11. 5292771 - Substituted .beta.-diketones and their use (1994-03-08),

12. 5288750 - Substituted .beta.-diketones (1994-02-22),

13. 5283352 - Pharmacologically active compounds, methods for the preparation thereof (1994-02-01),

14. 5185370 - Substituted .beta.-diketones and their use (1993-02-09),

15. 5151420 - Substituted pyridazinones (1992-09-29),

Title: Innovations and Contributions of Reijo J Backstrom in Pharmacology

Introduction

Reijo J Backstrom is a notable inventor based in Helsinki, Finland, recognized for his significant contributions to the field of pharmacology. With a remarkable portfolio of 19 patents, Backstrom has established himself as a key figure in the development of pharmacologically active compounds, particularly catechol derivatives.

Latest Patents

His latest patents involve innovative compounds that boast pharmacological activity. One such compound is defined by a formula where R1 is an electronegative substituent such as nitro, halogeno, or cyano group. Meanwhile, R2 consists of groups that can include hydrogen, straight or branched alkyls, phenyl, cycloalkyls, and more. These compositions are not only innovative but are also relevant in the prevention or treatment of tissue damage induced by lipid peroxidation. Moreover, they include pharmaceutically acceptable salts and esters, paving the way for advanced medical applications.

Career Highlights

Throughout his career, Backstrom has worked with esteemed organizations such as Orion-Yhtyma Oy and Orion Corporation, contributing to research and development initiatives that have pushed the boundaries of pharmaceutical science. His work focuses on creating compounds that have therapeutic potential, maximizing efficacy while minimizing side effects.

Collaborations

Reijo J Backstrom has collaborated with distinguished colleagues in his field, including Erkki J Honkanen and Inge-Britt Y Linden. These partnerships have resulted in fruitful research exchanges and innovative developments in the realm of pharmacology.

Conclusion

In conclusion, Reijo J Backstrom's contributions to the field of pharmacology, evidenced by his numerous patents and collaborations, accentuate his role as a trailblazer in medicinal chemistry. His innovative work continues to influence current and future pharmaceutical advancements, underscoring the importance of his research in the fight against various health challenges.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]